COPD Drug Pipeline: Biologics & Repair — PatSnap Eureka
COPD Drug Pipeline: Antiviral Triggers, Bronchodilator Biologics & Epithelial Repair
Patent signals from Regeneron, AstraZeneca, Genentech, and Boehringer Ingelheim reveal three converging innovation axes reshaping how the industry targets COPD exacerbations, airway inflammation, and alveolar damage.
The Molecular Architecture of COPD Innovation
COPD is a heterogeneous syndrome characterized by persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.70), airway and alveolar abnormalities, and chronic inflammatory immune responses to noxious particles or gases. According to WHO, COPD remains one of the leading causes of global morbidity and mortality.
Among retrieved patent and literature records, the dominant molecular targets are cytokines and their receptors—particularly the IL-33/ST2 axis, the IL-4/IL-13 shared receptor IL-4R, IL-5 receptor alpha (IL-5Rα), and IL-1R1—alongside structural and enzymatic targets including phosphodiesterase 4 (PDE4), muscarinic M3 receptors, matrix metalloproteinases (MMPs), and the chemokine receptor CXCR2.
IL-33 expression is reported to be elevated in COPD and inversely correlated with lung function, according to filings from MedImmune Limited. The ST2 axis (IL-33 receptor) is specifically described as modulating viral-triggered inflammatory cascades; retrieved data from Genentech indicate that ST2- or IL-33-deficient mice showed reduced inflammatory responses to respiratory viral infection without impairing antiviral host defense.
Biomarker-linked molecular targets DMBT1, KIAA1199, and TMSB15A—among a panel of over 30 genes—are identified in multiple filings from Transgenion GmbH as markers of progressive, irreversible lung damage, providing diagnostic stratification of COPD subtypes. R&D teams can explore these signals using PatSnap's IP analytics platform.
Biologic Agents Targeting Cytokine Axes
Monoclonal antibody-based blockade of epithelial-derived cytokine alarmins and their receptors dominates this dataset, spanning multiple jurisdictions and filing stages from 2019 to 2025.
IL-33 Antagonism: Tozorakimab & Regeneron/Sanofi Programs
Regeneron Pharmaceuticals and Sanofi Biotechnology have filed extensively across WO, US, AU, BR, TW, NZ, JP, and KR for anti-IL-33 antibodies covering treatment and prevention of COPD and reduction of AECOPD events. MedImmune Limited independently filed for tozorakimab (MEDI3506) at specific dosing regimens of 300–600 mg at Q4W or Q8W intervals, with one filing referencing an ongoing Phase III study (NCT05166889).
Phase III signal — NCT05166889IL-4R Blockade: Dupilumab-Class Expansion into COPD
Regeneron Pharmaceuticals and Sanofi Biotechnology co-filed multiple IL-4R antagonist patents (2024–2025) across WO, US, AU, IL, TW, and KR. Priority dates trace to early 2023 provisional applications, indicating rapid translation from the asthma indication. These claims target COPD patients via blocking the shared IL-4/IL-13 receptor, leveraging the type 2 inflammatory mechanism validated in atopic dermatitis and asthma.
2023–2025 priority datesBenralizumab: Biomarker-Enriched Patient Selection
AstraZeneca filed multiple patents for benralizumab in COPD across JP jurisdictions (2016–2025), specifically targeting eosinophil-high patient subpopulations (blood eosinophil count ≥300/µL), patients with ≥2 prior exacerbations per year, and those already on triple background therapy (ICS + LABA + LAMA). This represents a precision medicine approach using biomarker-enriched populations. Explore life sciences IP strategy on PatSnap's life sciences platform.
≥300/µL eosinophil thresholdGenentech ST2 Antagonist: Virus-Triggered Cascade Inhibition
Genentech filed for ST2 (IL-33 receptor) antagonism specifically for reducing annualized exacerbation rates by up to 45% vs. standard of care. Retrieved data explicitly link ST2 pathway inhibition to attenuating virus-induced inflammatory cascades in COPD. A Phase IIb, randomized, double-blind, placebo-controlled, multicenter study enrolling approximately 930 COPD patients evaluating an ST2 antagonist vs. SOC is referenced in retrieved filings.
Up to 45% exacerbation reduction vs. SOCTSLP Blockade: Extending the Alarmin-Blocking Paradigm
A retrieved filing from MedImmune LLC covers the use of an anti-thymic stromal lymphopoietin (TSLP) antibody for COPD treatment, extending the alarmin-blocking paradigm to the TSLP node. This complements IL-33 and IL-4R targeting with a third upstream alarmin pathway intervention.
TW filing 2025IL-1 Pathway Blockade for Acute Exacerbation Management
MedImmune Limited filed for anti-IL-1R1 and anti-IL-1α antibodies specifically targeting COPD exacerbations (2011–2013, WO, EP, MX), proposing that IL-1 pathway blockade reduces airway inflammation during acute episodes. CSL Behring also filed (JP, 2024) for aerosolized polyclonal immunoglobulin administered directly to the respiratory tract to prevent exacerbations driven by rhinovirus and other viral infections for which no approved respiratory antivirals exist.
WO, EP, MX filings 2011–2013COPD Pipeline Signals: Filing Activity & Target Distribution
Visualising patent filing activity and molecular target distribution across the COPD innovation landscape, derived from retrieved patent and literature records via PatSnap Eureka.
COPD Biologic Target Filing Volume (Relative)
IL-33/ST2 is the most represented target cluster by document count, followed by IL-4R and PDE4 programs spanning 2002–2025.
COPD Patent Filing Activity by Year Range
Two distinct program waves are visible: IL-33 programs from 2019 and IL-4R programs from 2023, alongside foundational small-molecule IP from 2002–2018.
Patent Assignee Cluster Distribution
Large pharma dominates filing activity; academic institutions contribute primarily to diagnostics and novel mechanistic hypotheses.
Clinical Translation Signals Detected in Patent Filings
Patent filing language reveals clinical stage signals from Phase III (tozorakimab) to pilot observational studies (doxycycline/MMP inhibition).
Bronchodilators, PDE4 Inhibitors & Anti-Inflammatory Combinations
Multiple retrieved patents describe small-molecule approaches targeting airway tone and pulmonary inflammation, spanning PDE4 inhibitors, LABA/LAMA fixed-dose combinations, and bifunctional agents.
| Compound / Class | Assignee | Mechanism | Filing Jurisdiction | Year |
|---|---|---|---|---|
| Nicotinamide derivatives (PDE4i) | Pfizer Products Inc. | PDE4 inhibition — reduces eosinophil activation, suppresses TNF-α and IL-8 | EP | 2002 |
| Quinoline derivatives (PDE4i) | GlaxoSmithKline | PDE4 inhibition — elevates intracellular cAMP, reduces neutrophil/eosinophil degranulation | Multiple | 2000s |
| Bifunctional quinoline (PDE4i + bronchodilation) | Gilead Sciences | Dual PDE4 inhibition + bronchodilation; claimed for irreversible/reversible airway obstruction and post-viral cough | Multiple | 2010s |
| Aminoester derivatives (dual PDE4i/M3) | Chiesi Farmaceutici / Chiesi Pharmaceuticals | Bifunctional: PDE4 inhibition + muscarinic M3 antagonism | ES | 2018 |
| PDE4i + Tiotropium (LAMA) combination | Boehringer Ingelheim Pharma | Inhaled combination addressing bronchodilation and inflammation simultaneously | ES, JP | 2007 |
| Fluticasone furoate + Vilanterol (ICS + LABA) | GlaxoSmithKline / Theravance | Fixed-dose inhaled combination — regulatory approval 2013 | Global | 2013 |
| Indacaterol + Glycopyrronium (LABA + LAMA, Ultibro) | Novartis | Fixed-dose LABA + LAMA combination — regulatory approval 2013 | Global | 2013 |
Map COPD Small-Molecule IP Across All Jurisdictions
Identify freedom-to-operate gaps and combination patent clusters with PatSnap Eureka's AI-powered search.
Epigenetic, Structural, and Alveolar Regeneration Approaches
Academic and translational institutions are pioneering mechanistically novel approaches targeting oxidative damage, epigenetic dysregulation, and alveolar cell regeneration in COPD.
Epigenetic Co-Delivery Systems (Tokyo Metropolitan University)
Liposome/biodegradable polymer carriers capable of simultaneously co-delivering antioxidants (to address reactive oxygen species [ROS]-mediated oxidative damage) and plasmid DNA encoding epigenetic regulatory enzymes. This approach addresses the dual COPD pathogenic mechanisms of oxidative damage and epigenetic dysregulation simultaneously. Filings in JP (2016 and 2020).
Curcuminoid Alveolar Regeneration (Sami-Sabinsa Group)
A composition enriched in bisdemethoxycurcumin (≥20% w/w) with demethoxycurcumin and curcumin, specifically described for regenerating damaged alveolar cells in emphysema and COPD, including COPD arising from viral infection (COVID-19). Filed as a CN patent in 2022, signalling a natural product-derived approach to structural repair.
LXR Agonists & miR-33 Antagonism for Emphysema (Columbia University)
Columbia University inventor Jeanine D'Armiento filed (US, 2016) for Liver X receptor (LXR) agonists, miR-33 antagonists, or TLR4/Myd88 pathway antagonists to treat COPD/emphysema, proposing cholesterol metabolism modulation and innate immune pathway dampening as repair-enabling mechanisms.
Type V Collagen Tolerization (Indiana University)
Indiana University Research and Technology Corporation filed for type V collagen (colV) or tolerizing fragments thereof as a treatment for COPD and asthma, proposing an immunotolerance-based mechanism to dampen aberrant airway immune responses. Filings in JP, CN, and HK (2012).
Biologics as Add-On to Triple Inhaled Therapy
AstraZeneca benralizumab filings specify that biologic add-on is deployed on top of ICS + LABA + LAMA triple therapy, formalizing the concept that biologics will complement rather than replace inhaled maintenance therapy. The retrieved MedImmune WO filing notes that even maximal triple therapy leaves 30–40% of patients with moderate-to-severe exacerbations, establishing the clinical rationale for biologic add-on.
Chiesi's dual PDE4i/M3 antagonist compounds represent a bifunctional small-molecule strategy, while Gilead's bifunctional quinoline derivatives combine PDE4 inhibition with bronchodilation in a single molecule. Boehringer Ingelheim's PDE4i + tiotropium combination formalizes the multi-target approach at the combination product level.
According to retrieved data, PDE4 inhibition elevates intracellular cAMP, reducing degranulation of eosinophils and neutrophils, suppressing TNF-α and IL-8, and relaxing airway smooth muscle—making PDE4 a mechanistically versatile anchor for combination strategies. Researchers in materials and chemical innovation can find analogous combination IP strategies on the PatSnap platform.
For neutrophilic COPD endotypes, retrieved academic data from the University of Manchester link IL-17 and IL-22 signaling to neutrophilic COPD, while Novartis filed for CXCR2-binding polypeptides specifically targeting neutrophil recruitment. The NIH and EMA continue to support clinical research frameworks for COPD endotype stratification.
COPD Drug Pipeline — key questions answered
The dominant molecular targets are cytokines and their receptors—particularly the IL-33/ST2 axis, the IL-4/IL-13 shared receptor IL-4R, IL-5 receptor alpha (IL-5Rα), and IL-1R1—alongside structural and enzymatic targets including phosphodiesterase 4 (PDE4), muscarinic M3 receptors, matrix metalloproteinases (MMPs), and the chemokine receptor CXCR2.
The strongest clinical signal in this dataset is tozorakimab (MEDI3506) from MedImmune Limited (AstraZeneca subsidiary). A retrieved filing from MedImmune explicitly references a Phase III, multicentre, randomised, double-blind, placebo-controlled study evaluating tozorakimab in COPD patients with exacerbation history (NCT05166889).
Retrieved data from Genentech indicate that the ST2 (IL-33 receptor) axis modulates viral-triggered inflammatory cascades; ST2- or IL-33-deficient mice showed reduced inflammatory responses to respiratory viral infection without impairing antiviral host defense. CSL Behring also filed for aerosolized polyclonal immunoglobulin to prevent exacerbations driven by rhinovirus and other viral infections for which no approved respiratory antivirals exist.
AstraZeneca filings for benralizumab specify enrollment criteria of blood eosinophil count ≥300/µL, ≥2 prior exacerbations per year, and triple background therapy (ICS + LABA + LAMA). Approximately 30% of COPD patients have elevated airway eosinophils, making eosinophilic inflammation a major stratification and therapeutic target. Transgenion GmbH filings also identify DMBT1, KIAA1199, and TMSB15A as markers of progressive, irreversible lung damage for diagnostic stratification.
Multiple retrieved patents describe small-molecule approaches including PDE4 inhibitors from Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, and Gilead. Boehringer Ingelheim filed for inhaled combinations of a PDE4 inhibitor and tiotropium (LAMA) to address both bronchodilation and inflammation simultaneously. Chiesi's dual PDE4i/M3 antagonist compounds represent a bifunctional small-molecule strategy. ReversPAH LLC filed for inhaled prostacyclin analogues combined with diethylcarbamazine or zileuton specifically for steroid-unresponsive COPD.
Emerging approaches include: Tokyo Metropolitan University's liposome/biodegradable polymer carriers co-delivering antioxidants and plasmid DNA encoding epigenetic regulatory enzymes; Sami-Sabinsa Group's curcuminoid composition enriched in bisdemethoxycurcumin (≥20% w/w) for regenerating damaged alveolar cells; Indiana University's type V collagen tolerization; Columbia University's LXR agonists and miR-33 antagonists targeting cholesterol metabolism and innate immune pathways; and doxycycline as a non-specific MMP inhibitor studied in a pilot observational study.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About COPD PatentsAccelerate Your COPD Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map IL-33, IL-4R, PDE4, and epithelial repair patent landscapes in minutes.
References
- Regeneron Pharmaceuticals, Inc. — Methods for treating COPD by administering an IL-33 antagonist (WO, 2021)
- MedImmune Limited — Treatment of Chronic Obstructive Pulmonary Disease With An Anti-Interleukin-33 Antibody (US, 2025)
- MedImmune Limited — Treatment of chronic obstructive pulmonary disease with anti-interleukin-33 antibodies (JP, 2024)
- Regeneron Pharmaceuticals, Inc. — Methods for treating COPD by administering an IL-4R antagonist (WO, 2024)
- Regeneron Pharmaceuticals, Inc. — Methods for treating COPD by administering an IL-4R antagonist (US, 2024)
- AstraZeneca AB — Methods for treating COPD in enriched patient populations using benralizumab (JP, 2025)
- AstraZeneca AB — Methods for treating COPD in enhanced patient population using benralizumab (JP, 2025)
- MedImmune LLC — Treatment of chronic obstructive pulmonary disease with Anti-TSLP antibody (TW, 2025)
- Genentech, Inc. — Method for treating chronic obstructive pulmonary disease with ST2 antagonists (JP, 2024)
- MedImmune Limited — Compositions and methods for treating COPD exacerbation (WO, 2011)
- Baadsgaard, Ole / Genmab A/S — CD20 binding molecules for the treatment of COPD (WO, 2008)
- Pfizer Products Inc. — Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes (EP, 2002)
- Chiesi Farmaceutici S.P.A. — Heteroaryl derivatives for the treatment of respiratory diseases (ES, 2018)
- Boehringer Ingelheim Pharma — Combination of PDE4 inhibitor and tiotropium (ES, 2007)
- Beeh, Insaf Respiratory Research Institute — Fixed-combination inhalers for COPD (2013 paper)
- ReversPAH LLC — Methods and compositions for treating COPD (US, 2022)
- Mereo BioPharma 1 Limited — Dosing regimens for AECOPD treatment (JP, 2019)
- Tokyo Metropolitan University — COPD treatment with epigenetic control carrier (JP, 2016)
- Sami-Sabinsa Group Limited — Composition for managing COPD (CN, 2022)
- Indiana University Research and Technology Corporation — Compositions for treating COPD and asthma (JP, 2012)
- D'Armiento, Jeanine (Columbia University) — Liver X receptor agonists in emphysema (US, 2016)
- Institute of Pulmocare and Research, Kolkata — Long-term doxycycline and lung function in COPD (2014 paper)
- CSL Behring AG — Methods for preventing acute exacerbations with polyclonal immunoglobulin (JP, 2024)
- Novartis AG — CXCR2 binding polypeptide (JP, 2013)
- University of Manchester — COPD, Neutrophils and Bacterial Infection: IL-17 and IL-22 (2015 paper)
- Harvard University — Methods for treatment of COPD and therapy monitoring (WO, 2016)
- F. Hoffmann-La Roche AG — Methods for treating exacerbations of inflammatory respiratory diseases (JP, 2024)
- Medical University of Vienna / Transgenion GmbH — Diagnosing COPD using molecular biomarkers (WO, 2015)
- Acceleron Pharma Inc. — ActRII proteins and uses thereof (JP, 2024)
- World Health Organization (WHO) — COPD global burden and mortality data
- National Institutes of Health (NIH) — COPD clinical research frameworks
- European Medicines Agency (EMA) — COPD endotype stratification guidance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.